DEA Moves to Tighten Grip on Another New Drug
Published Date: 5/26/2026
Proposed Rule
Summary
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Diphenidine Placed in Schedule I
DEA proposes to place diphenidine (including its salts and isomers) in Schedule I of the Controlled Substances Act. If finalized, anyone who handles or proposes to handle diphenidine—manufacturers, distributors, importers, exporters, researchers, or possessors—will be subject to the full regulatory controls, and administrative, civil, and criminal sanctions that apply to Schedule I substances.
Unauthorized Possession and Penalties
Possession of diphenidine in any quantity in a manner not authorized by the CSA would be unlawful and could subject a person to prosecution under the CSA. Persons unwilling or unable to obtain DEA registration must surrender or transfer all quantities of diphenidine to a DEA-registered person before the effective date of any final scheduling action.
DEA Registration Required to Handle
If the rule is finalized, any person who handles diphenidine would need to be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Persons who currently handle diphenidine and are not registered may not continue to handle it unless DEA approves their registration; a person already registered to conduct research with another Schedule I substance may continue research on diphenidine only if they submit a completed application or modification not later than 90 calendar days after the date the final rule takes effect.
New Security, Recordkeeping, and Quota Rules
Registered handlers of diphenidine would need to meet Schedule I security requirements, labeling and packaging rules, quota-based manufacturing limits, inventory and biennial inventory requirements, specific records and reports (including automated reporting), and DEA order form and import/export rules as set out in 21 U.S.C. and 21 CFR parts cited in the proposal. Disposal of stocks must comply with 21 CFR part 1317 and other applicable laws.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
Previous / Next Documents
Previous: 2026-10379 — Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA wants to remove certain inactive butalbital prescription products from their special exemption list because these products aren’t available anymore or the companies behind them are gone. This means these products will now be treated like controlled substances, not exempt ones. If you have thoughts, you’ve got until June 25, 2026, to speak up—no money changes for active products, just a cleanup of the list!
Next: 2026-10381 — Airworthiness Directives; Airbus SAS Airplanes
The FAA is updating safety rules for many Airbus A318, A319, A320, and A321 airplanes to fix a potential safety problem with certain parts. This update expands which parts are affected and applies to more planes, so operators need to check and possibly fix these parts soon. Comments on these changes are open until July 10, 2026, and following the new rules might cost some time and money but will keep flights safer.